|Articles|October 1, 2012

ACT June 2012 BPA

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Related Content

Imfinzi Regimen Demonstrates 22% Survival Benefit in Early Gastric and GEJ Cancer

ByNancy Ghattas,Andy Studna, Senior Editor

October 29th 2025

ACT Brief: AI Partnerships, Data-Driven Site Activation, and FDA Approval for Omvoh’s Single-Injection Regimen

ByAndy Studna, Senior Editor

October 29th 2025

Using Global Patient Data to Design Smarter, More Inclusive Clinical Trials

ByGen Li, PhD, MBA,Andy Studna, Senior Editor

October 29th 2025

Thermo Fisher, Lundbeck Announce New OpenAI Partnerships Advancing AI in Drug Development

ByAndy Studna, Senior Editor

October 28th 2025

ACT Brief: AI Expands Global Site Leadership as Ozempic Shows Potential to Reverse Biological Age

ByAndy Studna, Senior Editor

October 28th 2025

ACT June 2012 BPA

Newsletter

Related Content

Imfinzi Regimen Demonstrates 22% Survival Benefit in Early Gastric and GEJ Cancer

ACT Brief: AI Partnerships, Data-Driven Site Activation, and FDA Approval for Omvoh’s Single-Injection Regimen

Using Global Patient Data to Design Smarter, More Inclusive Clinical Trials

Thermo Fisher, Lundbeck Announce New OpenAI Partnerships Advancing AI in Drug Development

ACT Brief: AI Expands Global Site Leadership as Ozempic Shows Potential to Reverse Biological Age

Trending on Applied Clinical Trials Online

Thermo Fisher, Lundbeck Announce New OpenAI Partnerships Advancing AI in Drug Development

Imfinzi Regimen Demonstrates 22% Survival Benefit in Early Gastric and GEJ Cancer

ACT Brief: AI Partnerships, Data-Driven Site Activation, and FDA Approval for Omvoh’s Single-Injection Regimen

Accelerating Site Payments with Agentic AI: See it in Action

Using Global Patient Data to Design Smarter, More Inclusive Clinical Trials